Image of Bortezomib for the treatment of multiple myeloma (Review)

LITERATURE

Bortezomib for the treatment of multiple myeloma (Review)


Multiple myeloma is a malignancy of plasma cells accounting for approximately 1% of cancers and 12% of haematological malignancies.
The first-in-class proteasome inhibitor, bortezomib, is commonly used to treat newly diagnosed as well as relapsed/refractory myeloma,
either as single agent or combined with other therapies


Availability

Fonkozomib-001Available

Detail Information

Series Title
-
Call Number
-
Publisher : .,
Collation
-
Language
English
ISBN/ISSN
-
Classification
NONE
Content Type
-
Media Type
-
Carrier Type
-
Edition
-
Subject(s)
Specific Detail Info
Cochrane Database of Systematic Reviews 2016, Issue 4.
Statement of Responsibility

Other version/related

No other version available


File Attachment



Information


RECORD DETAIL


Back To Previous